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A wide array of immune cells, including lymphocytes, is known to be present and
to play a pathogenetic role in atherosclerotic lesions. However, limited information is
currently available regarding the presence of Natural Killer (NK) cell subsets within
vessel plaque, and more in general, regarding their role in human atherosclerosis. We
evaluated the distribution of NK cells in human carotid atherosclerotic plaques, dissecting
asymptomatic and symptomatic patients (identified as affected by stroke, transient
ischemic attack, or amaurosis fugax within 6 months) with the aim of shedding light
on the putative contribution of NK cells to the pathogenic process that leads to plaque
instability and subsequent clinical complications. We observed that carotid plaques were
consistently infiltrated by NK cells and, among them, CD56brightperforinlow NK cells were
abundantly present and displayed different markers of tissue residency (i.e., CD103
CD69 and CD49a). Interestingly, carotid atherosclerotic plaques of symptomatic patients
showed a higher content of NK cells and an increased ratio betweenCD56brightperforinlow
NK cells and their CD56dimperforinhigh counterpart. NK cells isolated from plaques
of symptomatic patients were also stronger producers of IFN-γ. Analysis of the
expression of NK activating receptor ligands (including MICA/B, ULBP-3, and B7-H6)
in atherosclerotic carotid plaques revealed that they were abundantly expressed by a
HLA-DR+CD11c+ myeloid cell population resident in the plaques. Remarkably, sera
of symptomatic patients contained significant higher levels of soluble ligands for NK
activating receptors. Our observations indicate that CD56bright NK cells accumulate
within human atherosclerotic lesions and suggest a possible contribution of NK cells
to the process determining plaque instability.
Keywords: natural killer cells, atherosclerosis, carotid atherosclerotic plaques, natural killer cell activating
receptors, interferon-γ, metalloproteases
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INTRODUCTION
Carotid atherosclerosisis is strongly associated with stroke
and cerebrovascular disease. Nevertheless, some carotid
atherosclerotic plaques (CAP) are stable and unlikely to produce
symptoms, whereas others are unstable and may induce
increased incidence of vascular complications. Symptomatic
plaques generally reveal intima rupture, a thinner fibrous cap and
a large necrotic core infiltrated bymacrophages and lymphocytes.
However, the complex molecular and cellular events underlying
plaque destabilization are not completely elucidated and different
immunological/inflammatory mechanisms are probably
responsible for the clinical complications associated with
unstable atherosclerotic plaques (AP). To further clarify the
multiple causes of carotid plaque destabilization, it would be
desirable to define a pathogenetic signature by characterizing
phenotypic and functional features of cells taking part not
only to plaque formation but also to the occurrence of
patient’s symptoms.
Immune cells, including innate lymphocytes such as Natural
Killer (NK) cells, have been previously reported to infiltrate
atherosclerotic lesions (1–3). NK cells are large granular
lymphocytes, divided in two main subsets: CD56dimCD16+cells
are the majority in human peripheral blood (PB) (≥95%) (4),
while CD56brightCD16− cells account for around 5% of NK
cells in PB but represent the majority of NK cells in several
peripheral tissues and in secondary lymphoid organs (5–7).
CD56dimCD16+NK cells display potent cytolytic activity, while
the CD56brightCD16− counterpart is mainly responsible for
cytokine production, primarily IFN-γ and TNF-α, but is poorly
cytolytic (6, 8). Although NK cells were mainly described in PB
and, more recently, in lymphoid tissues (8–10), it is now well-
established that NK cells can be recruited at inflammatory sites
(8, 10–12) and even enduringly reside in peripheral tissues at
steady state (13–15).
The presence of NK cells in APs has been previously
reported (1, 16–18) and it has also been shown that NKG2D,
a potent immune-activating receptor mainly expressed by
cytotoxic lymphocytes, including NK cells, plays a role in
the vicious cycle of chronic inflammation that promotes
atherosclerosis, since blocking NKG2D in mice reduced
inflammation and plaque progression in atherosclerotic lesions of
aorta (19).
It is noteworthy that Major Histocompatibility Complex
(MHC) class I-related chains A and B (MICA/B), which represent
major ligands of NKG2D receptor, are highly expressed in foam
cells infiltrating the fibrous cap as well as in the intra-plaque
hemorrhage space in atherosclerotic aortas of patients with type
2 diabetes mellitus (19). In agreement with these results, the
expression of MICA/B in human phagocytes was also confirmed
in vitro on foam cells derived from macrophages exposed to
modified low density lipoproteins (20). All these findings suggest
Abbreviations: KIR, killer Ig-like receptors; MMPs, metalloproteases;
NCRs, natural cytotoxicity receptors; NK, natural killer; AP, atherosclerotic
plaques; CAP, carotid atherosclerotic plaques; MMP, metalloprotease; IHC,
immunohystochemistry; IFN-γ, interferon-gamma.
a role for NKG2D in enhancing the inflammatory state in
atherosclerosis disease and support the hypothesis that NK cells
might be actively engaged in atherosclerotic lesions.
Given that other ligands for activating receptors specifically
expressed by NK cells, such as the NKp30 ligand B7-H6,
have been shown to be present on macrophage surface under
inflammatory conditions (21–23), we can hypothesize that
induction of these ligands might even occur in the context of the
inflammatory network of atherosclerosis.
Thus, on the basis of a possible contribution played
by NK cells in the pathogenesis of atherosclerosis, the
purpose of this study was to investigate whether the
frequency and functions of NK cells infiltrating CAP
might correlate with clinical complications occurring in
the patients.
MATERIALS AND METHODS
Patients and Samples
Fifty patients undergoing carotid endarterectomy at the Vascular
Surgery Unit of the University Hospital G. Martino of Messina
were enrolled in the study.
Patients were selected for invasive treatment according to the
European Society for Vascular Surgery (ESVS) guidelines
(24). Patients were evaluated with duplex-ultrasound.
The risk of stroke was predicted estimating the diameter
reduction of internal carotid artery (ICA) and evaluating
plaque morphology (25). Patients with symptoms of stroke,
transient ischemic attack (TIA) or amaurosis fugax within 6
months since diagnosis of carotid artery disease were defined
symptomatic (26–28).
All patients were admitted in the Vascular Surgery ward of
the University Hospital G. Martino of Messina 1 day before
the intervention. Carotid plaques were removed by eversion
carotid endarterectomy technique (24, 29) and pre-operative
blood samples were obtained from all patients. As control,
PB samples were obtained from age-matched individuals with
a similar gender distribution and <40% of carotid stenosis
assessed by ultrasonographic study. The study was approved
by our Institutional Ethics Committee and all patients gave
their written informed consent according to the Declaration
of Helsinki.
Carotid Plaque and Blood Sample
Processing
After surgical removal, carotid plaques were extensively
washed in phosphate-buffered saline (PBS) to remove
cell debris and red blood cells (RBC) aggregates. Samples
were then mechanically minced by scissors to obtain small
fragments. In order to minimize blood contamination,
tissue specimens were extensively rinsed after initial tissue
slashing in small fragments. Then, samples were enzymatically
digested with a mixture containing DNAse (100µg/ml;
Roche Diagnostics International Ltd., Rotkreuz, Switzerland)
and collagenase (1 mg/ml; Worthington, Lakewood, NJ) in
RPMI 1640 for 60min at 37◦C. The suspension was then
filtered through a cell strainer, and, subsequently, washed by
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centrifugation in PBS to remove residual enzyme. To obtain
mononuclear cells (MNCs), plaque cell suspensions or blood
underwent Ficoll-Hypaque (Sigma-Aldrich, St. Louis, Missouri)
density-gradient centrifugation.
Flow Cytometry
The following mouse anti-human mAbs were used in our
study: anti-CD3 PerCp Cy5.5 FITC (clone UCHT1), -CD16
PE-Cy7 (clone 3G8), -CD56 APC (clone NCAM 16.2), -
CD94 FITC (clone HP-3D9), -HLA-DR FITC/APC-H7/BV421
(clone G46-6), -CD11c PerCP-Cy5.5 (clone B-ly6), -CD45
APC-H7 (clone 2D1), -Perforin FITC (clone δG9), -CD103
BV421(clone Ber-ACT8), -CD49a PE (clone SR84), -CD69
APC/APC-H7 (clone FN50), -CD57 PE (clone NK-1), -CD19
FITC (clone HIB19) from BD Biosciences (San Jose, CA); -
perforin FITC (clone delta G9) from Ancell (Stillwater, MN);
-CD3 VioGreen (clone REA 613), -NKG2A PE-Vio770 (clone
REA 110), -NKG2C VioBright-FITC (clone REA205), -CD11c
(clone MJ4-27G12), and –MICA/B PE-Vio770 (clone 6D4), -
BDCA-2 FITC (clone AC144), -NKp30-PE (clone AF29-4D12)
from MiltenyiBiotec (Bergisch Gladbach, Germany); -ULBP-
3 PE (clone 166510), -B7-H6 APC (clone 875001) from
R&D (Minneapolis, MN); -CD16 Pacific Blue (clone 3G8)
from Beckman Coulter (Brea, CA). After incubation with the
relevant mAbs for 20min at 4◦C, cells were then washed and
analyzed by flow cytometry. Negative controls included isotype-
matched irrelevant Abs. Intracellular staining with anti-human
perforin-FITC was performed using the Fix/Perm kit from BD
Biosciences (San Jose, CA) according to the manufacturer’s
indications. Samples were then acquired using FACSCantoII (BD
Biosciences, San Jose, CA) and analyzed by FlowJo 9.0.2 software
(Tree Star).
Cytokine Production Assay
For the analysis of cytokine production, NK cells from carotid
plaques or autologous PB were stimulated with 10 ng/mL
phorbolmyristate acetate (PMA) and 500 ng/mL ionomycin
(both from Sigma-Aldrich, St. Louis, Missouri). After 45min,
Golgi Stop and Golgi Plug (both from BD Bioscience, San Jose,
CA) were added and stimulation was allowed to continue for a
total of 4 h. At the end of the stimulation, cells were first stained
for relevant surface markers and finally fixed and permeabilized
for intracellular detection of IFN-γ expression by specific mAb
(BD Biosciences, San Josè, CA).
RT-PCR Analysis
Total RNA was extracted from carotid plaques. Briefly,
samples were homogenized with Tissue Ruptor (Qiagen, Hilden,
Germany) and subsequently processed using RNeasy Fibrous
Tissue Mini Kit (Qiagen, Hilden, Germany). cDNA was prepared
using the Real Master Script Super Mix Kit (5-PRIME) following
manufacturer’s instructions. Amplifications were performed for
30 or 35 cycles utilizing Platinum TAQ DNA Polymerase
(ThermoFisher, Waltham, Massachusetts) with an annealing T of
58◦C. Primers used were: β-actin for 5′ ACTCCATCATGAAGT
GTGACG and β-actin rev 5′ CATACTCCTGCTTGCTGATCC;
MICA for 5′TACGATGGGGAGCTCTTC and MICA rev 5′
GACCCTCTGCAGCTGATG; MICB for 5′ TCCCGGCATT
TCTACTAC and MICB rev 5′ TGCATCCCTGTGGTCTCC;
H6 for 5′ TGCTGTGGGCGCTGACGA and H6 rev 5′ GGTA
GAACCCACTTGACTCA; ULBP-1 for 5′ TGCAGGCCAGG
ATGTCTTGT and ULBP-1 rev 5′ CATCCCTGTTCTTCTCC
CACTTC; ULBP-2 for 5′ CCCTGGGGAAGAAACTAAATGTC
and ULBP-2 rev 5′ ACTGAACTGCCAAGATCCACTGCT;
ULBP-3 for 5′ ATTCTTCCGTACCTGCTATT and ULBP-3
rev 5′ GCTATCCTTCTCCCACTTCT. PCR products (249 bp
fragment for β-actin, 618 bp for MICA, 698 bp for MICB,
462 bp for B7-H6, 171 bp for ULBP-1, 199 bp for ULBP-
2, and 492 bp for ULBP-3) were separated by electrophoresis
on a 1.5% (w/v) agarose gel and visualized by ethidium
bromide staining.
ELISA
Sera were processed using a serum separator tube (SST) and
samples were allowed to clot for 2 h at room temperature before
centrifugation for 15min at 1,000 × g. Samples were stored
at −20◦C prior analysis. To analyze the soluble ligands of NK
activating receptor MICA, ULBP-3 and B7-H6 (sMICA, sULBP-
3, and sB7-H6), ELISA was performed following manufacturer’s
instructions using the following reagents: ULBP-3 ELISA KIT
(Cusabio, Hubei Province, CN), MICA Duo ELISA Set (R&D,
Minneapolis, MN); B7-H6 Elisa Kit (MyBioSource, Inc., San
Diego, CA).
Statistical Analysis
We applied Kruskal-Wallis tests for evaluating quantitative
variables adjusting for multiple comparison using Dunn’s
correction. Graphic representation and statistical analysis were
performed using GraphPad Prism 6 (GraphPad Software La Jolla,
CA). Pearson correlation index was used to calculate correlation
for pair-wise continuous variables.
RESULTS
Clinical Characteristics of Patients
Out of 50 patients 16 were women (32%). Mean age was 71 ± 10
years (range 46–85). Twenty-one patients (42%) were diabetic, 28
(56%) were smokers, 35 (70%) had hypertension, and 31 (62%)
had hyperlipidemia. Thirty-one patients were asymptomatic
(62%) and 19 (38%) were symptomatic. Clinical characteristics
of patients and control individuals are summarized
in Table 1.
Symptomatic Carotid Plaques Are
Infiltrated by a Higher Number of NK Cells
To evaluate the presence of NK cells, we performed flow
cytometric analysis of cell suspensions obtained upon
dissociation of CAP from both symptomatic and asymptomatic
patients. NK cells isolated from CAP of 41 patients affected by
atherosclerotic disease of carotid artery (19 symptomatic and 22
asymptomatic) were analyzed in comparison to NK cells from
autologous PB. Since NK cells share their CD56 expression with
group 3 innate lymphoid cells (ILC3) (30), this latter subset
was excluded from the analyses on the basis of the absence
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TABLE 1 | Clinical characteristics of atherosclerotic patients and controls.
Symptomatic
(n = 19)
Asymptomatic
(n = 31)
Controls
(n = 15)
Age 72.6y (4.4) 71.4y (5.8) 69.0y (6.7)
Women 5 (26.3%) 11 (35.4%) 5 (33%)
Stroke 15 (78.9%) 0 0
TIA 3 (15.7%) 0 0
Amaurosis fugax 1 (5.2%) 0 0
Smoker 8 (42.1%) 20 (64.5%) 7 (47%)
Hypertension 15 (78.9%) 20 (64.5%) 8 (54%)
Diabetes status 7 (36.8%) 14 (45.1%) 5 (33%)
Hyperlipidemia 16 (84.2%) 15 (48.3%) 7 (47%)
Ischemic: heart disease 11 (57.8%) 8 (25.8%) 0
Plaque stenosis
70–80% 2 (10.5%) 3 (9.6%) 0
>80% 17 (89.4) 28 (90.3) 0
Categorical variables were reported as count (percentage). Continuous variable was
reported as mean ± standard deviation.
of CD94 and perforin (15, 30, 31). NK cells were consistently
detected in all the examined samples and we assessed the
relative frequency of the two main NK cell subsets, namely
CD56brightperforinlow and CD56dimperforinhigh NK cells. Due to
the possible downregulation of CD16 on NK cells extracted from
solid tissues (32, 33), we distinguished CD56dim from CD56bright
NK cells on the basis of perforin expression (Figure 1A). NK
cell frequency was higher in CAP isolated from symptomatic
patients whereas CAP from asymptomatic patients showed NK
cell frequency similar to PB (Figure 1B). NK cells isolated from
CAP of both symptomatic (sCAP) and asymptomatic (aCAP)
patients displayed a higher frequency of CD56brightperforinlow
NK cells when compared to autologous PB, and noteworthy,
sCAP showed the highest frequency of CD56bright perforinlow
NK cells (Figure 1C). As previously reported (16), no significant
difference in the frequency of NK cell subsets was observed
between PB of atherosclerotic patients and controls. In line
with their constitutive low expression of intracellular perforin,
CD56bright NK cells also presented low or undetectable surface
expression of CD16 and CD57, while they were typically positive
for NKG2A (Figure 2). Both NKG2D and NKp30 activating
receptors were homogenously expressed in all the samples
analyzed. Within the CD56dim subset a consistent fraction of
NK cells expressed NKG2C (Figure 2A and Figure S1A), while
markers of lymphocyte residency, such as CD103 (also known as
αE integrin), CD49a (also known as α1 integrin), and CD69 (14),
appeared confined to the CD56bright NK cell subset (Figure 2B),
suggesting a preferential migration of CD56bright NK cells
into CAP. However, no significant differences were observed
for these molecules between symptomatic and asymptomatic
patients (Figure S1B).
Carotid Plaque Tissues Express Ligands
for NK Cell Activating Receptors
Having observed the presence of distinct populations of NK
cells in CAP, a main question remained whether ligands for
FIGURE 1 | Characterization of NK cells from carotid atherosclerotic plaques
(CAP-NK). After processing carotid plaques, atheroma-resident mononuclear
cells were stained with relevant mAbs and analyzed by flow cytometry gating
on CD45+ lymphocytes. (A) Comparative analysis of total NK cells and of NK
cell subsets (i.e., CD56brightperforinlow and CD56dimperforinhigh cells) from
carotid atherosclerotic plaques (CAP-NK) and autologous PB (PB-NK). (B)
Percentage of total NK cells present in carotid plaques gating on CD45+
lymphocytes from symptomatic (sCAP-NK) and asymptomatic (aCAP-NK)
patients. (C) Percentage of CD56bright NK cells present in carotid plaques
gating on total NK cells. In (B) and in (C) NK cells from autologous peripheral
blood (PB-NK) were also analyzed as control. Kruskal-Wallis test was used to
determine statistical significance for group comparison. n.s., non-significant;
*p < 0.05 and ***p < 0.001.
their activating receptors were expressed by CAP tissues.
In agreement with previous reports (19), we found CAP
tissues consistently expressed significant levels of mRNA for
MICA, a main ligand for NKG2D receptor. In addition, we
found that B7-H6, a main cellular ligand for NKp30 receptor
(34), was also expressed in carotid plaques (Figure 3A).
MICB and ULBPs mRNA were detectable only in a fraction
of carotid plaques analyzed, and, among ULBP molecules,
ULBP-3 was the most frequently observed (Figure 3A
and Figure S2).
Thus, considering these results, we processed CAP tissues
and analyzed by flow cytometry, on the isolated cells, the protein
expression of the most represented ligands, revealing that
MICA/B (6 pts out of 10), ULBP-3 (4 pts out of 10), and B7-H6 (6
pts out of 10) were detectable in a CD45+HLA-DR+CD11c+lin
(CD3, CD19, CD94)neg cell population resident within
CAP (Figure 3B).
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FIGURE 2 | Expression of NK cell receptors and tissue resident markers on NK
cells from carotid atherosclerotic plaques (CAP-NK). (A) Expression of different
NK cell surface molecules was analyzed on carotid plaque NK cells from
(Continued)
FIGURE 2 | symptomatic patients (sCAP-NK), asymptomatic patients
(aCAP-NK), and on peripheral blood NK cells (PB-NK) of the same patients by
flow cytometry. Data shown are representative of at least five carotid plaques
showing similar results. No main differences were observed in PB of
symptomatic and asymptomatic patients. (B) Expression of tissue resident
markers (i.e., CD103, CD49a, and CD69) was analyzed on NK cells from
sCAP-NK, aCAP-NK, and PB-NK. Data shown are representative of at least
five carotid plaques showing similar results.
It is worth to note that although mRNA expression
of these ligands was detectable in the majority of the
samples, protein expression was detected in a smaller fraction,
which might reflect technical impediments associated to CAP
tissue processing.
Sera of Symptomatic CAP Patients Contain
Higher Levels of Soluble Ligands for
Activating NK Cell Receptors
Metalloproteases (MPPs) have been reported to play a role in
inducing AP instability (35, 36). Because these enzymes can also
cause the shedding of cellular ligands for NK activating receptors
(37–39), we investigated whether symptomatic CAP could be
associated with the release of soluble forms of NK activating
receptor ligands detected in CAP.
Soluble forms of the ligands were consistently increased in
the serum of atherosclerotic patients and sera levels of both
sMICA and sULBP-3 were significantly higher in symptomatic
patients (fold of increase CAP/Controls: 10 and 5.7 for
sMICA and sULBP-3, respectively) (Figure 4). In addition,
symptomatic patients displayed significant levels of sB7-H6,
which were undetectable in both asymptomatic patients and
controls (Figure 4).
IFN-γ Production by CAP-NK Is Associated
With Serum Levels of Soluble MICA
MMPs have been reported to be induced by IFN-γ (40), a major
cytokine produced by activated NK cells. Having observed
that CAP as well as sera of atherosclerotic patients contained
the ligands for NK activating receptors, we investigated
whether IFN-γ production by CAP-NK cells might be
associated with either plaque stability or release of soluble
NK activating ligands. We observed that NK cells isolated
from sCAP were more prone to produce IFN-γ (Figure 5A).
Remarkably, the frequency of IFN-γ+ NK cells in CAP
positively correlated with serum levels of sMICA (Figure 5B),
although no significant correlation was observed for other
soluble ligands.
DISCUSSION
Although previous studies demonstrated a functional role of
NK cells in different experimental models of atherosclerosis,
recent data derived from hypercolesterolemic mice failed to
find a definite role for NK cells in atherosclerosis development.
Nevertheless, they also demonstrated that NK cells might
exacerbate atherosclerosis in case of activation induced by viral
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FIGURE 3 | Expression of cellular ligands for NK cell activating receptors
within carotid atherosclerotic plaques (CAP). (A) mRNA expression of MICA,
B7-H6, and ULBP-3 was analyzed in CAP-specimens by PCR. Primers
specific for β-actin were utilized as positive control. Data shown are from
atheroma specimens obtained from four different patients, two symptomatic
(sCAP) and two asymptomatic (aCAP), and are representative of results
obtained with 10 different patients. (B) After processing CAP to single cell
suspension, mononuclear cells were analyzed by flow cytometry for the
expression of the main NK activating receptor ligands, which were detected on
a CD45+HLA-DR+CD11c+ lin (CD3, CD19, CD94)neg cell population (gray
histograms). Negative controls included isotype-matched irrelevant mAbs
(dark histograms).
infections (17), an event frequently occurring throughout the
whole life course. In agreement with this previous report, chronic
viral infections by CMV, which strongly activate NK cells, have
been shown to contribute to the inflammatory process leading
to the formation of AP (41–43) as well as to increase the risk
of vascular complications. Thus, it is conceivable that activation
of NK cells in these inflammatory contexts might contribute to
exacerbate atherosclerosis.
Because most of the current knowledge on human
NK cells in AP has been derived from investigations of
atherosclerotic lesions by immunohistochemistry, information
on phenotypic and functional features of NK cells involved
in this pathology was so far limited. Given the substantial
functional differences between the two main human circulating
NK cell subsets, the lack of information regarding the relative
distribution of CD56bright and CD56dim NK cells has so
far represented a major limitation for a comprehensive
understanding of the functional role of NK cells within the
immune network ruling CAP development. In this study, we
identified NK cells in CAP by multiparametric flow cytometric
analysis, also corroborating previous results obtained by
IHC (1, 44, 45).
The analysis of NK cell subsets revealed that CAP were
enriched in CD56bright perforinlow/neg NK cells as compared with
autologous PB. The frequency of CD56bright NK cells was even
higher in plaques of symptomatic patients compared to that of
asymptomatic ones, suggesting their preferential accumulation
in the microenvironment of unstable plaques or, on the other
hand, their potential contribution in plaque destabilization.
This finding is in line with the distribution of chemokine
receptor ligands leading to NK cell migration in AP, as it has
been recently demonstrated that CCL19 and CCL21, the major
chemokines dictating CCR7-dependent migration of CD56bright
NK cells, are upregulated in atherosclerotic carotid plaques of
symptomatic patients as compared to asymptomatic ones (46,
47). Remarkably, we observed that CD56bright CAP-NK cells
selectively express variable levels of tissue resident markers, i.e.,
CD103, CD49a, CD69, which are absent in the CD56dimsubset
as well as in PB-NK cells, suggesting that CD56bright NK
cells might preferentially be recruited to the plaque and then
up-regulate markers of tissue residency under the influence
of local inflammation. Our current observations are also in
agreement with former studies showing that CD56bright NK
cells, a cell subset particularly prone to cytokine production,
often represent the main NK cell population in other inflamed
tissues (48).
In line with previous reports showing the expression of
MICA/B in atherosclerotic lesion (19) and of B7-H6 under
inflammatory conditions (21), we observed that MICA/B, B7-
H6, and ULBP-3 were expressed in CAP by large/scattered
cells of myeloid origin compatible with a macrophagic/dendritic
cell phenotype. It is likely that foam cells, derived from
monocytes recruited upon inflammatory conditions within the
intima of atherosclerotic lesions, might express ligands for
activating NK receptors, since this event has been shown to
occur, at least for some NK activating receptor ligands, in
the presence of oxidized low density lipoproteins (20, 21).
However, we could not exclude that other cell subsets residing
within carotid plaques or endothelial cells might also express
these ligands in the inflammatory microenvironment of the
vessel. Further analyses are needed to explore in deeper details
AP cellular components that might represent cell targets for
NK cells.
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FIGURE 4 | Assessment of soluble ligands for NK cell activating receptors in the sera of patients affected by carotid atherosclerotic plaques. Soluble ligands for NK
activating receptors (sMICA, sB7-H6, sULBP-3) were assessed in the serum of symptomatic (Symp, black bars), of asymptomatic (Asymp, white bars) patients and of
controls (Ctrl, gray bars) by ELISA; Bars represent mean values ± SD from 10 symptomatic, 19 asymptomatic patients and 10 control individuals. Kruskal-Wallis text
was the used to determine statistical significance for group comparison. n.s., non-significant; *p < 0.05, **p < 0.01, and ***p < 0.001.
FIGURE 5 | IFN-γ production by NK cells isolated from carotid plaques
(CAP-NK). (A) IFN-γ production was assessed in NK cells from carotid plaques
of symptomatic (sCAP-NK) and asymptomatic (aCAP-NK) patients after 4 h of
stimulation with PMA and ionomycin. Dot plots shown are representative of 12
patients (five symptomatic and seven asymptomatic). Kruskal-Wallis test was
used to determine statistical significance for group comparison. Bars represent
mean value ± SD of the frequency of IFN-γ+ NK cells in carotid plaques from
symptomatic (white bar) and asymptomatic patients (black bar). (B) The
Pearson correlation coefficient was calculated between serum levels of soluble
MICA and IFN-γ+ NK cells isolated from CAP. *p < 0.05 and **p < 0.01.
Overall, our observations might suggest the existence, within
the atherosclerotic lesions, of an inflammatory pathway sustained
by NK cells recognizing their activating ligands on macrophage-
like cells or other cells expressing the ligands in CAP tissue, with
a consequent release of IFN-γ able to boost the inflammatory
process. This assumption is also supported by previous reports
describing in AP direct contacts between CD56+ cells, assumed
to be bona fide NK cells, and macrophages (1). Thus, because
CAP-NK cells constitutively express both NKp30 and NKG2D at
levels similar to PB-NK (Figure S3), they can be actively triggered
by target cells expressing ligands for these receptors within CAP.
Remarkably, NK cells in symptomatic patients were stronger
IFN-γ producers. Given that IFN-γ has been shown to behave
as a pro-atherogenic cytokine, also causing plaque destabilization
through either the induction of smooth muscle cell apoptosis
or the release of MMPs (40), it might be envisaged that CAP-
resident NK cells might contribute to both plaque formation
and destabilization by massively secreting this cytokine. IFN-
γ produced by CAP-NK cells, by inducing MMP production,
might also contribute to determine ligand shedding. This
hypothesis is further sustained by the observation that the
frequency of IFN-γ+ NK cells correlated with serum levels
of sMICA.
In conclusions, our data indicate that CD56bright NK cells
might play a role in the progression of the atherosclerotic
process within carotid plaques by exerting a pro-inflammatory
effect upon recognition of cell targets within CAP. The evidence
that soluble forms of NK activating receptor ligands are both
increased in symptomatic patients and associated with the
amount of CAP IFN-γ+ NK cells, also favors the hypothesis
that NK cell-derived IFN-γ might contribute to the production,
within AP, of MMPs able, on the one hand, to shed these soluble
forms (38, 39) and, on the other, to critically affect CAP stability
(35, 36) and hence its clinical consequences.
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